Search

Your search keyword '"Nilles EJ"' showing total 65 results

Search Constraints

Start Over You searched for: Author "Nilles EJ" Remove constraint Author: "Nilles EJ"
65 results on '"Nilles EJ"'

Search Results

2. Phylogeographical analysis of the dominant multidrug-resistant H58 clade of Salmonella Typhi identifies inter-and intracontinental transmission events

4. Convergence of SARS-CoV-2 spike antibody levels to a population immune setpoint.

5. Hand hygiene perceptions, preferences, and practices among hospital staff in the Dominican Republic in the context of COVID-19: a qualitative study.

6. Using Regional Sero-Epidemiology SARS-CoV-2 Anti-S Antibodies in the Dominican Republic to Inform Targeted Public Health Response.

7. Monitoring Temporal Changes in SARS-CoV-2 Spike Antibody Levels and Variant-Specific Risk for Infection, Dominican Republic, March 2021-August 2022.

8. Diagnostic TR-FRET assays for detection of antibodies in patient samples.

9. Tracking immune correlates of protection for emerging SARS-CoV-2 variants.

10. SARS-CoV-2 seroprevalence, cumulative infections, and immunity to symptomatic infection - A multistage national household survey and modelling study, Dominican Republic, June-October 2021.

11. Humanitarian Training With Virtual Simulation During a Pandemic.

12. Longitudinal SARS-CoV-2 Nucleocapsid Antibody Kinetics, Seroreversion, and Implications for Seroepidemiologic Studies.

13. mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions.

14. Serological Markers of SARS-CoV-2 Reinfection.

15. SARS-CoV-2 antibodies protect against reinfection for at least 6 months in a multicentre seroepidemiological workplace cohort.

16. mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern.

17. Epidemiological and Immunological Features of Obesity and SARS-CoV-2.

18. Evaluation of Three Commercial and Two Non-Commercial Immunoassays for the Detection of Prior Infection to SARS-CoV-2.

19. Early cross-coronavirus reactive signatures of humoral immunity against COVID-19.

20. Subtle immunological differences in mRNA-1273 and BNT162b2 COVID-19 vaccine induced Fc-functional profiles.

21. Early cross-coronavirus reactive signatures of protective humoral immunity against COVID-19.

22. Interactions between timing and transmissibility explain diverse flavivirus dynamics in Fiji.

23. Humoral signatures of protective and pathological SARS-CoV-2 infection in children.

24. Discrete SARS-CoV-2 antibody titers track with functional humoral stability.

25. Epidemiological and immunological features of obesity and SARS-CoV-2.

27. SARS-CoV-2 Serosurvey in Addis Ababa, Ethiopia.

28. Rapid 'mix and read' assay for scalable detection of SARS-CoV-2 antibodies in patient plasma.

29. Tenacious Endemic Typhoid Fever in Samoa.

30. First evidence of concurrent enzootic and endemic transmission of Ross River virus in the absence of marsupial reservoirs in Fiji.

31. Evaluation of two commercial and two non-commercial immunoassays for the detection of prior infection to SARS-CoV-2.

32. Dynamics of conflict during the Ebola outbreak in the Democratic Republic of the Congo 2018-2019.

33. Sustained Low-Level Transmission of Zika and Chikungunya Viruses after Emergence in the Fiji Islands.

34. Institutional trust and misinformation in the response to the 2018-19 Ebola outbreak in North Kivu, DR Congo: a population-based survey.

35. Ross River Virus Antibody Prevalence, Fiji Islands, 2013-2015.

36. Environmental health effects attributed to toxic and infectious agents following hurricanes, cyclones, flash floods and major hydrometeorological events.

37. Predictive risk mapping of an environmentally-driven infectious disease using spatial Bayesian networks: A case study of leptospirosis in Fiji.

38. A Large Leptospirosis Outbreak following Successive Severe Floods in Fiji, 2012.

39. Zika Virus Infection during Pregnancy and Effects on Early Childhood Development, French Polynesia, 2013-2016.

40. Using paired serology and surveillance data to quantify dengue transmission and control during a large outbreak in Fiji.

41. Re-emergence of thiamine deficiency disease in the Pacific islands (2014-15): A case-control study.

42. Methicillin resistant Staphylococcus Aureus in emergency department patients in the United Arab Emirates.

43. Use of geographically weighted logistic regression to quantify spatial variation in the environmental and sociodemographic drivers of leptospirosis in Fiji: a modelling study.

44. Facing the Shortage of IV Fluids - A Hospital-Based Oral Rehydration Strategy.

45. Role of Environmental Factors in Shaping Spatial Distribution of Salmonella enterica Serovar Typhi, Fiji.

46. Social mixing in Fiji: Who-eats-with-whom contact patterns and the implications of age and ethnic heterogeneity for disease dynamics in the Pacific Islands.

47. A cross-sectional seroepidemiological survey of typhoid fever in Fiji.

48. Epidemiological Investigation of a Diarrhea Outbreak in the South Pacific Island Nation of Tuvalu During a Severe La Niña-Associated Drought Emergency in 2011.

49. Investigation of a Guillain-Barré syndrome cluster in the Republic of Fiji.

50. Early warning epidemic surveillance in the Pacific island nations: an evaluation of the Pacific syndromic surveillance system.

Catalog

Books, media, physical & digital resources